Related Experiment Video

Updated: Jul 12, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?

Ruben D Restrepo1

  • 1Department of Respiratory Care, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 6248, San Antonio TX 78229-3900, USA. restrepor@uthscsa.edu.edu

Respiratory Care
|August 25, 2007
PubMed

Insights

Pulmonary mucociliary clearance is vital for lung defense. While bronchodilators are used to improve airway clearance in obstructive lung diseases, their clinical effectiveness remains inconsistent.

Area of Science:

  • Pulmonary physiology
  • Respiratory medicine
  • Mucociliary clearance mechanisms

Background:

  • Pulmonary mucociliary clearance is a critical defense mechanism against inhaled pathogens and particles.
  • Dysfunction of mucociliary clearance is a hallmark of obstructive lung diseases, including COPD, asthma, cystic fibrosis, and bronchiectasis.
  • Impaired airway clearance contributes to accelerated lung function decline in patients with obstructive lung conditions.

Purpose of the Study:

  • To evaluate the therapeutic role of bronchodilators as mucoactive agents in obstructive lung diseases.
  • To investigate the effectiveness of anticholinergic and adrenergic agonist bronchodilators in enhancing mucociliary clearance.
  • To assess the clinical utility of bronchodilators in managing mucus hypersecretion and improving lung function.

Main Methods:

  • Review of existing evidence on bronchodilator use for mucociliary clearance.
  • Analysis of studies investigating anticholinergic and adrenergic agonist effects on mucus secretion and transport.
  • Examination of clinical trials assessing the impact of bronchodilators on lung function and airway clearance in obstructive lung diseases.

Main Results:

  • Cholinergic and adrenergic pathways are implicated in mucus hypersecretion, suggesting a potential role for bronchodilators.
  • Anticholinergic and adrenergic agonist bronchodilators are commonly employed to improve mucociliary clearance.
  • Current evidence does not consistently demonstrate the clinical effectiveness of these bronchodilators in enhancing mucociliary clearance.

Conclusions:

  • Bronchodilators have a theoretical basis for use as mucoactive agents due to their neural pathway involvement.
  • Despite routine use, the clinical effectiveness of bronchodilators in improving mucociliary clearance is not consistently supported by evidence.
  • Further research may be needed to clarify the role and optimize the use of bronchodilators in managing obstructive lung diseases characterized by mucociliary dysfunction.

More Related Videos

In vivo Evaluation of Mucociliary Clearance in Mice06:35

In vivo Evaluation of Mucociliary Clearance in Mice

Published on: December 18, 2020

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...